This has been already demonstrated for EGFR-mutations detection by ctDNA analysis [29–31] in EGFR-positive NSCLC patients but need to be further investigated for cPD-L1 and other potential biomarkers detected in the blood of NSCLC patients receiving ICIs. Here, EGFR is linked to non-small cell lung carcinoma.